View in EDS

Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.

Saved in:
Bibliographic Details
Title: Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
Authors: Chiang ST; Oncology Wards & Phase I Center, Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan., Chueh CH; Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, San Diego, CA, USA., Wen YW; Department of Biomedical Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Chiang SC; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.; The Center of Advanced Pharmacy Education, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Li WH; Gynecologic Robotic and Minimally Invasive Surgery Center, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan. liwaihou@yahoo.com.tw., Tsai YW; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Medical AI Development Center, Taipei Veterans General Hospital, Taipei, Taiwan. ywtsai@nycu.edu.tw.
Source: Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2026 Jan 14; Vol. 24 (1). Date of Electronic Publication: 2026 Jan 14.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101170476 Publication Model: Electronic Cited Medium: Print ISSN: 1478-7547 (Print) Linking ISSN: 14787547 NLM ISO Abbreviation: Cost Eff Resour Alloc Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41535916
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chiang+ST%22">Chiang ST</searchLink>; Oncology Wards & Phase I Center, Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chueh+CH%22">Chueh CH</searchLink>; Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wen+YW%22">Wen YW</searchLink>; Department of Biomedical Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chiang+SC%22">Chiang SC</searchLink>; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.; The Center of Advanced Pharmacy Education, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Li+WH%22">Li WH</searchLink>; Gynecologic Robotic and Minimally Invasive Surgery Center, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan. liwaihou@yahoo.com.tw.<br /><searchLink fieldCode="AU" term="%22Tsai+YW%22">Tsai YW</searchLink>; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.; Medical AI Development Center, Taipei Veterans General Hospital, Taipei, Taiwan. ywtsai@nycu.edu.tw.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101170476%22">Cost effectiveness and resource allocation : C/E</searchLink> [Cost Eff Resour Alloc] 2026 Jan 14; Vol. 24 (1). <i>Date of Electronic Publication: </i>2026 Jan 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101170476 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>1478-7547 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214787547%22">14787547 </searchLink><i>NLM ISO Abbreviation: </i>Cost Eff Resour Alloc <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41535916
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12962-025-00711-y
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chiang ST
      – PersonEntity:
          Name:
            NameFull: Chueh CH
      – PersonEntity:
          Name:
            NameFull: Wen YW
      – PersonEntity:
          Name:
            NameFull: Chiang SC
      – PersonEntity:
          Name:
            NameFull: Li WH
      – PersonEntity:
          Name:
            NameFull: Tsai YW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 01
              Text: 2026 Jan 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 1478-7547
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cost effectiveness and resource allocation : C/E
              Type: main
ResultId 1